Divalproex Sodium (Depakote) + Lamotrigine (Lamictal)
FDA label language suggests this combination may require monitoring, dose adjustment, or added caution. Make sure every prescriber involved in your care knows you take both.
Basis: Boxed warning of the Lamotrigine FDA label.
In addition to age, factors that may increase the risk of occurrence or the severity of rash caused by lamotrigine include (1) coadministration of lamotrigine with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of lamotrigine, (3) exceeding the recommended dose escalation for lamotrigine, or (4) the presence of the HLA-B*1502 allele However, cases have occurred in the absence of these factors.
Excerpt from the FDA prescribing label for Lamotrigine (SPL set ID 003663e5-c0c7-4fc1-a64d-313f2a5b10d2).
About this interaction data. These interactions were identified by automatically scanning FDA prescribing-label text for medications in Bridgeway's library. This is not a complete list and is not a substitute for review by your prescriber or pharmacist, who use comprehensive clinical databases. Always share your full medication list with your care team. How we source this data →
Bridgeway's Utah prescribers coordinate medication management with therapy — so interactions like this one are reviewed by people who see your whole picture.
Request an Appointment Call (801) 255-5131Not medical advice. This page summarizes publicly available FDA drug labeling alongside general guidance from Bridgeway Integrated Healthcare Services. It is for educational purposes only and is not a substitute for advice from your prescriber or pharmacist. Never start, stop, or change a medication without talking to your healthcare provider. In an emergency, call 911.